<DOC>
	<DOCNO>NCT01398189</DOCNO>
	<brief_summary>To examine feasibility molecular imaging marker clinical psychopharmacology</brief_summary>
	<brief_title>F-18 Altanserin PET Study Patients Receiving Clozapine</brief_title>
	<detailed_description>Clinical evaluation patient psychiatric disorder mainly dependent patient ' report clinician ' observation . In order develop objective quantifiable measure psychopathology , molecular imaging technique use patient receive clozapine .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>Overtly healthy male determine medical history physical examination Age 19 45 year Weight ≥ 45 kg within ± 20 % IBW Clinical laboratory test result within normal reference range National Cancer Center , Hospital result minor deviation judge clinically significant investigator Normal blood pressure heart rate ( supine standing ) determine investigator Are reliable willing make available duration study , abide study restriction Have give write informed consent Evidence significant active hematologic disease History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , neurological disorder capable alter absorption , metabolism elimination drug , constitute risk factor take study medication An episode febrile disease infectious disease within past 2 week Evidence significant active neuropsychiatric disease Regular use drug abuse History drug hypersensitivity clinically significant allergic reaction origin Participation study involve administration investigational compound within past 30 day Use current medication Smoking history recent 3 month</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>clozapine</keyword>
	<keyword>PET</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
</DOC>